Azelastine hydrochloride/fluticasone propionate co

Authors: Greg L Plosker Katherine A LysengWilliamson

Publish Date: 2015/10/13

Volume: 31, Issue: 12, Pages: 425-432

PDF Link

Abstract

Azelastine hydrochloride/fluticasone propionate 137/50 μg nasal spray henceforth MPAzeFlu Dymista® provides a combination of two firstline treatments for allergic rhinitis an intranasal antihistamine and an intranasal corticosteroid in a single spray In 14day clinical trials in patients with allergic rhinitis MPAzeFlu improved nasal and ocular symptoms to a significantly greater extent than placebo or monotherapy with its individual active components either marketed products or products reformulated in the MPAzeFlu formulation MPAzeFlu’s novel formulation contributes to its efficacy MPAzeFlu provided more rapid relief of symptoms than either azelastine or fluticasone monotherapy and consistent benefits were demonstrated regardless of disease severity or symptoms The beneficial effects of MPAzeFlu have also been shown with long term treatment and in the clinical practice setting The most frequently reported adverse events with MPAzeFlu are dysgeusia epistaxis and headacheThe manuscript was reviewed by P Devillier Hôpital Foch Suresnes France R Hermann Clinical Research Appliance Radolfzell Germany J Mullol Institut d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS Barcelona Spain D Ryan Woodbrook Medical Centre Loughborough UK U Wahn Charité Medical University Berlin Germany During the peer review process the manufacturer of MPAzeFlu was also offered an opportunity to review this article Changes resulting from comments received were made on the basis of scientific and editorial merit

Keywords: